© 2017 Elsevier Ltd Toxicities related to osimertinib have been reported with lower incidence and grade as compared to other tyrosin kinase inhibitors. The present report includes previously unreported adverse events related to osimertinib. These toxicities are a reminder of potential novel toxicities related to new drugs and highlight the need for a multidisciplinary approach to recognize and treat such adverse events.
|Journal||Cancer Treatment and Research Communications|
|Publication status||Published - 1 Jan 2017|
- Epidermal growth factor receptor (EGFR)
- Nasal vestibulitis
- Skin adverse events